Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy-Reference-Cited by-同舟云学术

Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy

Published:2023-08 Issue:4 Volume:21 Page:e228-e235.e1
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Khan Maira^ORCID,Parshad Shruti,Naimi Mahdi F.,Sidhu Amanjot K.,Lyons Frank^ORCID,Hardisty Michael R.,Whyne Cari M.,Smoragiewicz Martin^ORCID,Phillips Cameron M.,Briones Juan,Emmenegger Urban^ORCID

Funder

Joseph and Silvana Melara Cancer Research Fund

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference27 articles.

1. Targeting bone metastases in prostate cancer: improving clinical outcome;Body;Nat Rev Urol,2015

2. Alpha emitter radium-223 and survival in metastatic prostate cancer;Parker;N Engl J Med,2013

3. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial;Smith;Lancet Oncol,2019

4. Osteosarcopenia: epidemiology, diagnosis, and treatment-facts and numbers;Kirk;J Cachexia Sarcopenia Muscle,2020

5. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival;Ryan;Nutrition,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive value-based method for new nuclear medical service pricing: with case study of radium [223Ra] bone metastases treatment;BMC Health Services Research;2024-03-29